Skip to main content
. 2021 Apr 6;9:617589. doi: 10.3389/fcell.2021.617589

FIGURE 6.

FIGURE 6

Human bone marrow–derived mesenchymal stem cell (hBMSC)–derived exosomes alleviated the manifestations of acute graft-versus-host disease (aGVHD) in mice. Mice in the exosome injection group were injected with 200 μg exosomes per mouse via tail vein on the day of transplantation. Recombinant mouse IL-10 was intravenously injected into aGVHD mice with a dose of 5 μg/kg every other day (injection volume 50 μl) in the IL-10 treatment group starting from day 0. For TNF-α inhibition, mice were injected intraperitoneally with etanercept (Merck) at a dose of 5 mg/kg body weight every 3 days starting from day 0 and the animals in the control group received injections of saline. No exosome was used in IL-10 and etanercept treated mice. (A) Weight changes of aGVHD mice in each treatment group. (B) Clinical score of aGVHD mice in each treatment group. (C) Survival curves of aGVHD mice in each treatment group. TBI, total body irradiation. ***p < 0.001, **p < 0.001, *p < 0.05. N = 10 in each group.